1
|
Steven A, Rossi S, Dasso N, Napolitano F, Grosso A, Villa S, Aleo G, Catania G, Sasso L, Zanini M, Bagnasco A. Corrigendum to "A qualitative exploration of undergraduate nursing students' experience of emotional safety for learning during their clinical practice" [Nurse Educ. Today. 121 2023, 105,673]. Nurse Educ Today 2023; 129:105783. [PMID: 36933952 DOI: 10.1016/j.nedt.2023.105783] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/18/2023]
Affiliation(s)
- A Steven
- Department of Nursing, Midwifery and Health, Faculty of Health and Life sciences, Coach Lane Campus West, Northumbria University, Newcastle upon Tyne NE7 7XA, UK.
| | - S Rossi
- IRCCS Istituto Giannina Gaslini, Via Gerolamo Gaslini, 5, 16147 Genova, GE, Italy
| | - N Dasso
- IRCCS Istituto Giannina Gaslini, Via Gerolamo Gaslini, 5, 16147 Genova, GE, Italy
| | - F Napolitano
- Department of Health Sciences, University of Genoa, Via A. Pastore, 1, 16132 Genoa, Italy.
| | - A Grosso
- Accident & Emergency Department, Evangelic International Hospital, Piazzale Efisio Gianasso, 4, 16158 Genoa, Italy
| | - S Villa
- Anaesthesia and Intensive Care Unit, IRCCS Teaching Hospital San Martino Policlinic, Largo R. Benzi, 10, 16132 Genoa, Italy
| | - G Aleo
- Department of Health Sciences, University of Genoa, Via A. Pastore, 1, 16132 Genoa, Italy; Faculty of Nursing & Midwifery, Royal College of Surgeons in Ireland, 123 St Stephen's Green, Dublin, Ireland.
| | - G Catania
- Department of Health Sciences, University of Genoa, Via A. Pastore, 1, 16132 Genoa, Italy.
| | - L Sasso
- Department of Health Sciences, University of Genoa, Via A. Pastore, 1, 16132 Genoa, Italy.
| | - M Zanini
- Department of Health Sciences, University of Genoa, Via A. Pastore, 1, 16132 Genoa, Italy.
| | - A Bagnasco
- Department of Health Sciences, University of Genoa, Via A. Pastore, 1, 16132 Genoa, Italy.
| |
Collapse
|
2
|
Spruijt I, Erkens C, Greenaway C, Mulder C, Raviglione M, Villa S, Zenner D, Lönnroth K. Reducing the burden of TB among migrants to low TB incidence countries. Int J Tuberc Lung Dis 2023; 27:182-188. [PMID: 36855037 DOI: 10.5588/ijtld.22.0662] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/02/2023] Open
Abstract
BACKGROUND: International migrants to low TB incidence countries are disproportionately affected by TB compared to the native population: migrants are at increased risk for TB transmission and TB disease due to a variety of personal, environmental and socio-economic determinants experienced during the four phases of migration (pre-departure, transit, arrival and early settlement, return travel).OBJECTIVE: To provide an up-to-date overview of the determinants that drive the TB burden among migrants, as well as effective and feasible interventions to address this for each migration phase.METHODS: We conducted a literature review by searching PubMed and the grey literature for articles and reports on determinants and interventions addressing migrant health and TB.RESULTS: Lowering the risk of TB transmission and TB disease among migrants would be most effective by improving the socio-economic position of migrants pre-, during and after migration, ensuring universal health coverage, and providing tailored and migrant-sensitive care and prevention activities.CONCLUSION: In addition to migrant-sensitive health services and cross-border collaboration between low TB incidence countries, there is a need for international financial and technical support for endemic countries.
Collapse
Affiliation(s)
- I Spruijt
- Division TB Elimination and Health System Innovations, KNCV Tuberculosis Foundation, The Hague, The Netherlands
| | - C Erkens
- Division TB Elimination and Health System Innovations, KNCV Tuberculosis Foundation, The Hague, The Netherlands
| | - C Greenaway
- Division of Infectious Diseases and Clinical Epidemiology, McGill University, Montreal, QC, Canada
| | - C Mulder
- Division TB Elimination and Health System Innovations, KNCV Tuberculosis Foundation, The Hague, The Netherlands
| | - M Raviglione
- Centre for Multidisciplinary Research in Health Science (MACH), Università di Milano, Milan, Italy
| | - S Villa
- Centre for Multidisciplinary Research in Health Science (MACH), Università di Milano, Milan, Italy
| | - D Zenner
- Wolfson Institute of Population Health, Queen Mary University, London, UK
| | - K Lönnroth
- Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden
| |
Collapse
|
3
|
Villa S, Carugati M, Rubach MP, Cleaveland S, Mpagama SG, Khan SS, Mfinanga S, Mmbaga BT, Crump JA, Raviglione MC. 'One Health´ approach to end zoonotic TB. Int J Tuberc Lung Dis 2023; 27:101-105. [PMID: 36853111 DOI: 10.5588/ijtld.22.0393] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
Mycobacterium bovis has a wide host range causing TB in animals, both in wildlife and cattle (bovine TB bTB), and in humans (zoonotic TB zTB). The real burden of bovine and zoonotic TB (b/zTB) remains unknown due to diagnostic challenges. Although progress has been made to reduce the burden of TB, b/zTB has been neglected in low- and middle-income countries (LMICs) with little improvement in prevention, diagnosis or treatment. Using Tanzania as a case study, because of its high TB burden, large wildlife diversity and wide reliance on livestock, we developed an approach to comprehensively estimate the burden and implement multidisciplinary actions against b/zTB. We performed a review of the literature on b/zTB, but there is a lack of available data on the b/zTB burden in Tanzania and, notably, on epidemiological indicators other than incidence. We propose a five-action programme to address b/zTB in Tanzania, and we believe our proposed approach could benefit other LMICs as it operates by implementing and strengthening surveillance and health delivery. The resulting knowledge and system organisation could further prevent and mitigate the effects of such conditions on human and animal health, livestock production, population livelihood and the economy.
Collapse
Affiliation(s)
- S Villa
- Centre for Multidisciplinary Research in Health Science, University of Milan, Milan, Italy
| | - M Carugati
- Division of Infectious Diseases and International Health, Duke University, Durham, NC, USA
| | - M P Rubach
- Division of Infectious Diseases and International Health, Duke University, Durham, NC, USA, Duke Global Health Institute, Duke University, Durham, NC, USA, Kilimanjaro Christian Medical University College, Moshi, Tanzania
| | - S Cleaveland
- Institute of Biodiversity, Animal Health and Comparative Medicine, University of Glasgow, Glasgow, UK
| | - S G Mpagama
- Kilimanjaro Christian Medical University College, Moshi, Tanzania, Kibong´oto Infectious Diseases Hospital, Moshi, Tanzania
| | - S S Khan
- Humanitas University, Milan, Italy
| | - S Mfinanga
- National Institute for Medical Research - Muhimbili Centre, Dar es Salaam, Tanzania, Liverpool School Tropical Medicine, Liverpool, UK
| | - B T Mmbaga
- Kilimanjaro Christian Medical University College, Moshi, Tanzania, Kilimanjaro Clinical Research Institute, Kilimanjaro Christian Medical Centre, Moshi, Tanzania
| | - J A Crump
- Division of Infectious Diseases and International Health, Duke University, Durham, NC, USA, Duke Global Health Institute, Duke University, Durham, NC, USA, Kilimanjaro Christian Medical University College, Moshi, Tanzania, Centre for International Health, University of Otago, Dunedin, New Zealand
| | - M C Raviglione
- Centre for Multidisciplinary Research in Health Science, University of Milan, Milan, Italy
| |
Collapse
|
4
|
Villa S, Sánchez I, Fernandez-Aranda F, Custal N, Menchón J, Alonso P. Clinical predictors of hepatic complications in Anorexia Nervosa. Eur Psychiatry 2022. [PMCID: PMC9567127 DOI: 10.1192/j.eurpsy.2022.978] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Introduction
Hepatic ones are some of the most described somatic complications in anorexia nervosa (AN) affected patients. They can be due to malnutrition, which is the more usual thing, or due to re-feeding. The first one can lead to more marked elevations of the hepatic enzymes, especially alanine-aminotransferase (ALT). It’s been also described the relation between a sharply decreased body mass index (BMI) and this kind of complications, but there are still to determine more predictors.
Objectives
Identifying clinical predictors of hepatic complications in AN.
Methods
We analysed data from 71 AN affected patients hospitalized at Bellvitge Hospital from January 2016 to October 2021. We used IBM SPSS Statistics 22 to do all the statistics in this work.
Results
The medium age of the sample was 27.66 years with 10.8 years of evolution of AN. The medium BMI was 13.88. 33.80% of them had some sort of hepatic enzymes elevation, two of them a several one. AST, ALT and ALP were significantly more elevated in those patients with lower BMI. GGT was significantly more elevated in patients with more years of disorder development. We didn’t identify correlation between any purgative method and hepatic alterations.
Conclusions
The elevation of ALT, AST and ALP seems to be related with the BMI of the patients, while the elevation of the GGT turns out to be related to the time of evolution of the eating disorder. Purgative methods don’t seem to be related to the development of hepatic alterations in AN.
Disclosure
No significant relationships.
Collapse
|
5
|
Thulasi Seetha S, Garanzini E, Messina A, Tenconi C, Marenghi C, Avuzzi B, Catanzaro M, Stagni S, Villa S, Noris Chiorda B, Badenchini F, Panchakumar J, Bertocchi E, Pignoli E, Valdagni R, Casale A, Nicolai N, Rancati T. PO-1595 Automated stability study on mpMRI prostate radiomics features to variations in segmentation. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)03559-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
6
|
Omelyanchik A, Villa S, Vasilakaki M, Singh G, Ferretti AM, Ponti A, Canepa F, Margaris G, Trohidou KN, Peddis D. Interplay between inter- and intraparticle interactions in bi-magnetic core/shell nanoparticles. Nanoscale Adv 2021; 3:6912-6924. [PMID: 36132365 PMCID: PMC9418531 DOI: 10.1039/d1na00312g] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/27/2021] [Accepted: 09/17/2021] [Indexed: 06/15/2023]
Abstract
The synthesis strategy and magnetic characterisation of two systems consisting of nanoparticles with core/shell morphology are presented: an assembly of hard/soft nanoparticles with cores consisting of magnetically hard cobalt ferrite covered by a magnetically soft nickel ferrite shell, and the inverse system of almost the same size and shape. We have successfully designed these nanoparticle systems by gradually varying the magnetic anisotropy resulting in this way in the modulation of the magnetic dipolar interactions between particles. Both nanoparticle systems exhibit high saturation magnetisation and display superparamagnetic behaviour at room temperature. We have shown strong exchange coupling at the core/shell interface of these nanoparticles systems which was also confirmed by mesoscopic modelling. Our results demonstrate the possibility of modulating magnetic anisotropy not only by chemical composition but also by adopting the proper nano-architecture.
Collapse
Affiliation(s)
- A Omelyanchik
- Department of Chemistry and Industrial Chemistry (DCIC), University of Genova Genova Italy
- Immanuel Kant Baltic Federal University Kaliningrad Russia
| | - S Villa
- Department of Chemistry and Industrial Chemistry (DCIC), University of Genova Genova Italy
| | - M Vasilakaki
- Institute of Nanoscience and Nanotechnology, National Center for Scientific Research Demokritos Athens 15310 Greece
| | - G Singh
- Engineering School of Biomedical Engineering, Sydney Nano Institute, The University of Sydney Sydney Australia
| | - A M Ferretti
- Istituto di Scienze e Tecnologie Chimiche "Giulio Natta" Via G. Fantoli 16/15 20138 Milano Italy
| | - A Ponti
- Istituto di Scienze e Tecnologie Chimiche "Giulio Natta" Via C. Golgi 19 20133 Milano Italy
| | - F Canepa
- Department of Chemistry and Industrial Chemistry (DCIC), University of Genova Genova Italy
| | - G Margaris
- Institute of Nanoscience and Nanotechnology, National Center for Scientific Research Demokritos Athens 15310 Greece
| | - K N Trohidou
- Institute of Nanoscience and Nanotechnology, National Center for Scientific Research Demokritos Athens 15310 Greece
| | - D Peddis
- Department of Chemistry and Industrial Chemistry (DCIC), University of Genova Genova Italy
- Istituto di Struttura Della Materia, CNR 00015 Monterotondo Scalo RM Italy
| |
Collapse
|
7
|
deantoni C, Fodor A, Cozzarini C, Tummineri R, Sanchez Galvan A, Villa S, Baroni S, Mandurino G, Pacifico P, Castriconi R, Fiorino C, Di Muzio N. PD-0910 Radical radiotherapy in lymph node or bone metastatic prostate cancer: a single institution series. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07189-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
8
|
Balana C, Vaz MA, Manuel Sepúlveda J, Mesia C, Del Barco S, Pineda E, Muñoz-Langa J, Estival A, de Las Peñas R, Fuster J, Gironés R, Navarro LM, Gil-Gil M, Alonso M, Herrero A, Peralta S, Olier C, Perez-Segura P, Covela M, Martinez-García M, Berrocal A, Gallego O, Luque R, Perez-Martín FJ, Esteve A, Munne N, Domenech M, Villa S, Sanz C, Carrato C. A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01). Neuro Oncol 2021; 22:1851-1861. [PMID: 32328662 DOI: 10.1093/neuonc/noaa107] [Citation(s) in RCA: 56] [Impact Index Per Article: 18.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND Standard treatment for glioblastoma is radiation with concomitant and adjuvant temozolomide for 6 cycles, although the optimal number of cycles of adjuvant temozolomide has long been a subject of debate. We performed a phase II randomized trial investigating whether extending adjuvant temozolomide for more than 6 cycles improved outcome. METHODS Glioblastoma patients treated at 20 Spanish hospitals who had not progressed after 6 cycles of adjuvant temozolomide were centrally randomized to stop (control arm) or continue (experimental arm) temozolomide up to a total of 12 cycles at the same doses they were receiving in cycle 6. Patients were stratified by MGMT methylation and measurable disease. The primary endpoint was differences in 6-month progression-free survival (PFS). Secondary endpoints were PFS, overall survival (OS), and safety (Clinicaltrials.gov NCT02209948). RESULTS From August 2014 to November 2018, 166 patients were screened, 7 of whom were ineligible. Seventy-nine patients were included in the stop arm and 80 in the experimental arm. All patients were included in the analyses of outcomes and of safety. There were no differences in 6-month PFS (control 55.7%; experimental 61.3%), PFS, or OS between arms. MGMT methylation and absence of measurable disease were independent factors of better outcome. Patients in the experimental arm had more lymphopenia (P < 0.001), thrombocytopenia (P < 0.001), and nausea and vomiting (P = 0.001). CONCLUSIONS Continuing temozolomide after 6 adjuvant cycles is associated with greater toxicity but confers no additional benefit in 6-month PFS. KEY POINTS 1. Extending adjuvant temozolomide to 12 cycles did not improve 6-month PFS.2. Extending adjuvant temozolomide did not improve PFS or OS in any patient subset.3. Extending adjuvant temozolomide was linked to increased toxicities.
Collapse
Affiliation(s)
- Carmen Balana
- Medical Oncology Service, Institut Català d'Oncologia, Badalona, Spain.,Applied Research Group in Oncology (B-ARGO) from the Institut Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP), Badalona, Spain
| | | | | | - Carlos Mesia
- Medical Oncology Service, Institut Català d'Oncologia, Hospitalet de Llobregat, Spain
| | - Sonia Del Barco
- Medical Oncology Service, Institut Català d'Oncologia Girona, Girona, Spain
| | - Estela Pineda
- Medical Oncology Service, Hospital Clinic de Barcelona, Barcelona, Spain
| | - Jose Muñoz-Langa
- Medical Oncology Service, Hospital Universitario La Fe, Valencia, Spain
| | - Anna Estival
- Medical Oncology Service, Institut Català d'Oncologia, Badalona, Spain.,Applied Research Group in Oncology (B-ARGO) from the Institut Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP), Badalona, Spain
| | - Ramón de Las Peñas
- Medical Oncology Service, Hospital Provincial de Castellón, Castellón, Spain
| | - Jose Fuster
- Medical Oncology Service, Hospital Son Espases, Palma De Mallorca, Spain
| | - Regina Gironés
- Medical Oncology Service, Hospital Universitario La Fe, Valencia, Spain
| | | | - Miguel Gil-Gil
- Medical Oncology Service, Institut Català d'Oncologia, Hospitalet de Llobregat, Spain.,Bellvitge Biomedical Research Institute (IDIBELL) Hospitalet de Llobregat, Spain
| | - Miriam Alonso
- Medical Oncology Service, Hospital Virgen del Rocio, Sevilla, Spain
| | - Ana Herrero
- Medical Oncology Service, Hospital Miguel Servet, Zaragoza, Spain
| | - Sergio Peralta
- Medical Oncology Service, Hospital Sant Joan de Reus, Reus, Spain
| | - Clara Olier
- Medical Oncology Service, Fundación Alcorcón, Madrid, Spain
| | - Pedro Perez-Segura
- Medical Oncology Service, Hospital Universitario Clínico San Carlos, Madrid, Spain
| | - Maria Covela
- Medical Oncology Service, Hospital Lucus Agusti, Lugo, Spain
| | | | - Alfonso Berrocal
- Medical Oncology Service, Hospital General Universitario de Valencia, Valencia, Spain
| | - Oscar Gallego
- Medical Oncology Service, Hospital de Sant Pau, Barcelona, Spain
| | - Raquel Luque
- Medical Oncology Service, Hospital Universitario Virgen de las Nieves, Granada, Spain
| | - Franciso Javier Perez-Martín
- Medical Oncology Service, Institut Català d'Oncologia, Hospitalet de Llobregat, Spain.,Bellvitge Biomedical Research Institute (IDIBELL) Hospitalet de Llobregat, Spain
| | - Anna Esteve
- Applied Research Group in Oncology (B-ARGO) from the Institut Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP), Badalona, Spain
| | - Nuria Munne
- Pathology Service, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
| | - Marta Domenech
- Medical Oncology Service, Institut Català d'Oncologia, Badalona, Spain
| | - Salvador Villa
- Radiation Therapy Oncology Service, Institut Català d'Oncologia, Badalona, Spain
| | - Carolina Sanz
- Pathology Service, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
| | - Cristina Carrato
- Pathology Service, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
| |
Collapse
|
9
|
Vecchié A, Bonaventura A, Meessen J, Novelli D, Minetti S, Elia E, Ferrara D, Ansaldo AM, Scaravilli V, Villa S, Ferla L, Caironi P, Latini R, Carbone F, Montecucco F. PCSK9 is associated with mortality in patients with septic shock: data from the ALBIOS study. J Intern Med 2021; 289:179-192. [PMID: 32686253 DOI: 10.1111/joim.13150] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/25/2020] [Revised: 05/31/2020] [Accepted: 06/05/2020] [Indexed: 12/11/2022]
Abstract
BACKGROUND Pro-protein convertase subtilisin/kexin 9 (PCSK9) is a proenzyme primarily known to regulate low-density lipoprotein receptor re-uptake on hepatocytes. Whether PCSK9 can concurrently trigger inflammation or not remains unclear. Here, we investigated the potential association between circulating levels of PCSK9 and mortality in patients with severe sepsis or septic shock. METHODS Plasma PCSK9 levels at days 1, 2 and 7 were measured in 958 patients with severe sepsis or septic shock previously enrolled in the Albumin Italian Outcome Sepsis (ALBIOS) trial. Correlations between levels of PCSK9 and pentraxin 3 (PTX3), a biomarker of disease severity, were evaluated with ranked Spearman's coefficients. Cox proportional hazards models were used to assess the association of PCSK9 levels at day 1 with 28- and 90-day mortality. RESULTS Median plasma PCSK9 levels were 278 [182-452] ng mL-1 on day 1. PCSK9 correlated positively with PTX3 at the three time-points, and patients with septic shock within the first quartile of PCSK9 showed higher levels of PTX3. Similar mortality rates were observed in patients with severe sepsis across PCSK9 quartiles. Patients with septic shock with lower PCSK9 levels on day 1 (within the first quartile) showed the highest 28- and 90-day mortality rate as compared to other quartiles. CONCLUSION In our sub-analysis of the ALBIOS trial, we found that patients with septic shock presenting with lower plasma PCSK9 levels experienced higher mortality rate. Further studies are warranted to better evaluate the pathophysiological role of PCSK9 in sepsis.
Collapse
Affiliation(s)
- A Vecchié
- From the, First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, Genoa, Italy.,Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA
| | - A Bonaventura
- From the, First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, Genoa, Italy.,Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA
| | - J Meessen
- Department of Cardiovascular Medicine, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
| | - D Novelli
- Department of Cardiovascular Medicine, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
| | - S Minetti
- From the, First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, Genoa, Italy.,IRCCS Ospedale Policlinico San Martino Genova - Italian Cardiovascular Network, Genoa, Italy
| | - E Elia
- From the, First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, Genoa, Italy
| | - D Ferrara
- From the, First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, Genoa, Italy
| | - A M Ansaldo
- From the, First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, Genoa, Italy
| | - V Scaravilli
- Department of Anesthesia, Critical Care and Emergency, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milano, Italy
| | - S Villa
- Dipartimento di Anestesia e Rianimazione, Università degli Studi Milano Bicocca, ASST Monza, Monza, Italy
| | - L Ferla
- Dipartimento Emergenza Urgenza - Rianimazione, Azienda Socio Sanitaria Territoriale - Ovest Milanese, Ospedale di Legnano, Legnano, Italy
| | - P Caironi
- Department of Anesthesia and Critical Care, AOU San Luigi Gonzaga, Department of Oncology, University of Turin, Orbassano, Turin, Italy
| | - R Latini
- Department of Cardiovascular Medicine, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
| | - F Carbone
- From the, First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, Genoa, Italy.,IRCCS Ospedale Policlinico San Martino Genova - Italian Cardiovascular Network, Genoa, Italy
| | - F Montecucco
- IRCCS Ospedale Policlinico San Martino Genova - Italian Cardiovascular Network, Genoa, Italy.,First Clinic of Internal Medicine, Department of Internal Medicine and Centre of Excellence for Biomedical Research (CEBR), University of Genoa, Genoa, Italy
| | | |
Collapse
|
10
|
Esteve-Codina A, Alameda F, Carrato C, Pineda E, Arpí O, Martinez-García M, Mallo M, Gut M, Dabad M, Tortosa A, Del Barco S, Capellades J, Puig J, Gallego O, Pujol T, Oleaga L, Gil-Gil M, de Quintana-Schmidt C, Valduvieco I, Martinez-Cardús A, Bellosillo B, Muñoz-Marmol AM, Esteve A, Domenech M, Camins A, Craven-Bartle J, Villa S, Marruecos J, Domenech S, de la Iglesia N, Balana C. RNA sequencing and Immunohistochemistry Reveal ZFN7 as a Stronger Marker of Survival than Molecular Subtypes in G-CIMP-negative Glioblastoma. Clin Cancer Res 2020; 27:645-655. [PMID: 33106291 DOI: 10.1158/1078-0432.ccr-20-2141] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2020] [Revised: 09/21/2020] [Accepted: 10/21/2020] [Indexed: 11/16/2022]
Abstract
PURPOSE Glioblastoma is the most aggressive brain tumor in adults and has few therapeutic options. The study of molecular subtype classifications may lead to improved prognostic classification and identification of new therapeutic targets. The Cancer Genome Atlas (TCGA) subtype classification has mainly been applied in U.S. clinical trials, while the intrinsic glioma subtype (IGS) has mainly been applied in European trials. EXPERIMENTAL DESIGN From paraffin-embedded tumor samples of 432 patients with uniformly treated, newly diagnosed glioblastoma, we built tissue microarrays for IHC analysis and applied RNA sequencing to the best samples to classify them according to TCGA and IGS subtypes. RESULTS We obtained transcriptomic results from 124 patients. There was a lack of agreement among the three TCGA classificatory algorithms employed, which was not solely attributable to intratumoral heterogeneity. There was overlapping of TCGA mesenchymal subtype with IGS cluster 23 and of TCGA classical subtype with IGS cluster 18. Molecular subtypes were not associated with prognosis, but levels of expression of 13 novel genes were identified as independent prognostic markers in glioma-CpG island methylator phenotype-negative patients, independently of clinical factors and MGMT methylation. These findings were validated in at least one external database. Three of the 13 genes were selected for IHC validation. In particular, high ZNF7 RNA expression and low ZNF7 protein expression were strongly associated with longer survival, independently of molecular subtypes. CONCLUSIONS TCGA and IGS molecular classifications of glioblastoma have no higher prognostic value than individual genes and should be refined before being applied to clinical trials.
Collapse
Affiliation(s)
- Anna Esteve-Codina
- CNAG-CRG, Centre for Genomic Regulation, Barcelona Institute of Science and Technology, Barcelona, Spain
| | - Francesc Alameda
- Pathology Department, Neuropathology Unit, Hospital del Mar, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain
| | - Cristina Carrato
- Pathology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
| | - Estela Pineda
- Medical Oncology, Hospital Clínic, Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain
| | - Oriol Arpí
- Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain
| | | | - Mar Mallo
- Institut de Recerca Contra la Leucèmia Josep Carreras, Badalona, Spain
| | - Marta Gut
- CNAG-CRG, Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Universitat Pompeu Fabra (UPF), Barcelona, Spain
| | - Marc Dabad
- CNAG-CRG, Centre for Genomic Regulation, Barcelona Institute of Science and Technology, Barcelona, Spain
| | - Avelina Tortosa
- Laboratori de Quimio-resistència i Cáncer, School of Medicine and Health Sciences, University of Barcelona, Department of Fundamental Care and Medical-Surgical Nursing, Bellvitge Biomedical Research Institute (IDIBELL), Bellvitge, Spain
| | - Sonia Del Barco
- Medical Oncology, Institut Catala d'Oncologia (ICO), Hospital Josep Trueta, Girona, Spain
| | | | - Josep Puig
- Radiology Department, Institut de Diagnòstic per la Imatge, Hospital Josep Trueta, Girona, Spain
| | - Oscar Gallego
- Medical Oncology, Hospital de Sant Pau, Barcelona, Spain
| | - Teresa Pujol
- Radiology Department, Hospital Clínic, Barcelona, Spain
| | - Laura Oleaga
- Radiology Department, Hospital Clínic, Barcelona, Spain
| | - Miquel Gil-Gil
- Neuro-Oncology Unit & Medical Oncology Department, Institut Catala d'Oncologia (ICO), Institut de Investigació Bellvitge (IDIBELL), L'Hospitalet, Barcelona, Spain
| | | | | | - Anna Martinez-Cardús
- Institut Catala d'Oncologia (ICO), Badalona Applied Research Group in Oncology (B-ARGO Group), Institut Investigació Germans Trias i Pujol (IGTP), Badalona, Spain
| | - Beatriz Bellosillo
- Pathology Department, Neuropathology Unit, Hospital del Mar, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain
| | | | - Anna Esteve
- Institut Catala d'Oncologia (ICO), Badalona Applied Research Group in Oncology (B-ARGO Group), Institut Investigació Germans Trias i Pujol (IGTP), Badalona, Spain
| | - Marta Domenech
- Institut Catala d'Oncologia (ICO), Badalona Applied Research Group in Oncology (B-ARGO Group), Institut Investigació Germans Trias i Pujol (IGTP), Badalona, Spain
| | - Angels Camins
- Radiology Department, Institut de Diagnòstic per la Imatge, Hospital de Bellvitge, Bellvitge, Spain
| | | | - Salvador Villa
- Radiation Therapy Department, Institut Catala d'Oncologia (ICO), Badalona, Spain
| | - Jordi Marruecos
- Radiation Oncology Department, Institut Catala d'Oncologia (ICO), Girona, Spain
| | - Sira Domenech
- Radiology Department, Institut de Diagnòstic per la Imatge, Hospital Germans Trias i Pujol, Badalona, Spain
| | - Nuria de la Iglesia
- Glioma and Neural Stem Cell Group, Translational Genomics and Targeted Therapeutics in Solid Tumors Team, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain
| | - Carmen Balana
- Institut Catala d'Oncologia (ICO), Badalona Applied Research Group in Oncology (B-ARGO Group), Institut Investigació Germans Trias i Pujol (IGTP), Badalona, Spain.
| |
Collapse
|
11
|
Villa S, Druelle C, Juliéron M, Nicot R. [3D-assisted mandibular reconstruction: A technical note of fibula free flap with preshaped titanium plate]. ANN CHIR PLAST ESTH 2020; 66:174-179. [PMID: 32753249 DOI: 10.1016/j.anplas.2020.07.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2020] [Revised: 06/23/2020] [Accepted: 07/01/2020] [Indexed: 10/23/2022]
Abstract
The purpose of this technical note is to illustrate a simple and economical preoperative method for preshaping a reconstructive titanium plate in a fibula free flap (FFF) by using 3D printing of a virtually reconstructed mandible haptic model. The whole process consisted in creating a 3D model of the patient's mandible based on a CT-scan using a combination of free software (3Dslicer and ITK-snap), and simulating the surgical osteotomies and reconstruction, and print it as a guide for bending a reconstruction titanium plate. Reconstruction is performed using virtual cubes (1 to 3 cubes, according the number of FFF osteotomies). This virtual lab work is performed using 3D Builder® (Microsoft, Redmond) software. This technique allows obtaining an optimal plate application on the bony fragments. It facilitates reconstructive surgery with good functional (putting the patient back in an optimal dental occlusion based on the native maxilla) and aesthetic results. This technical note presents a simple and economical preoperative fabrication of a reconstructive plate through freeware and a low-cost 3D printer accessible to all surgeons.
Collapse
Affiliation(s)
- S Villa
- Service de chirurgie maxillo-faciale et stomatologie, university de Lille, hôpital R.-Salengro, CHU de Lille, 2, avenue Oscar-Lambret, 59037 Lille cedex, France; Centre Oscar-Lambret, centre de lutte contre le cancer, service de chirurgie cervico-faciale, Lille, France.
| | - C Druelle
- Service de chirurgie maxillo-faciale et stomatologie, university de Lille, hôpital R.-Salengro, CHU de Lille, 2, avenue Oscar-Lambret, 59037 Lille cedex, France
| | - M Juliéron
- Centre Oscar-Lambret, centre de lutte contre le cancer, service de chirurgie cervico-faciale, Lille, France
| | - R Nicot
- Inserm, service de chirurgie maxillo-faciale et stomatologie, U1008 - Controlled Drug Delivery Systems and Biomaterials, university de Lille, CHU de Lille, 59000 Lille, France
| |
Collapse
|
12
|
Badenchini F, Marenghi C, Avuzzi B, Bellardita L, Casale A, Catanzaro M, Claps M, Colecchia M, De Luca L, Di Florio T, Donegani S, Dordoni P, Macchi A, Messina A, Morlino S, Noris Chiorda B, Stagni S, Tesone A, Torelli T, Villa S, Zollo F, Magnani T, Rancati T, Valdagni R, Nicolai N. A predictive model to personalize follow up schedules for patients in active surveillance. EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)33880-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
13
|
Pineda E, Esteve-Codina A, Martinez-Garcia M, Alameda F, Carrato C, Arpi O, Aldecoa I, Menendez S, Ribalta T, Vidal Sarro N, Berron SDB, Estival A, Gallego O, Gil Gil MJ, Mesia Barroso C, Craven J, Villa S, Fuentes R, de la Iglesia N, Balana C. Glioblastoma gene expression subtypes and correlation with clinical, molecular and immunohistochemical characteristics in a homogenously treated cohort: GLIOCAT project. J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.15_suppl.2029] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2029 Background: Glioblastoma (GBM) gene expression subtypes have been described in last years, data in homogeneously treated patients is lacking. Methods: Clinical, molecular and immunohistochemistry (IHC) analysis from patients with newly diagnosed GBM homogeneously treated with standard radiochemotherapy were studied. Samples were classified based on the expression profiles into three different subtypes (classical, mesenchymal, proneural) using Support Vector Machine (SVM), the K-nearest neighbor (K-NN) and the single sample Gene Set Enrichment Analysis (ssGSEA) classification algorithms provided by GlioVis web application. Results: GLIOCAT Project recruited 432 patients from 6 catalan institutions, all of whom received standard first-line treatment (2004 -2015). Best paraffin tissue samples were selected for RNAseq and reliable data were obtained from 124. 82 cases (66%) were classified into the same subtype by all three classification algorithms. SVM and ssGEA algorithms obtain more similar results (87%). No differences in clinical variables were found between the 3 GBM subtypes. Proneural subtype was enriched with IDH1 mutated and G-CIMP positive tumors. Mesenchymal subtype (SVM) was enriched in unmethylated MGMT tumors (p = 0.008), and classical (SVM) in methylated MGMT tumors (p = 0.008). Long survivors ( > 30 months) were rarely classified as mesenchymal (0-7.5%) and were more frequently classified as Proneural (23.1-26.). Clinical (age, resection, KPS) and molecular ( IDH1, MGMT) known prognostic factors were confirmed in this serie. Overall, no differences in prognosis were observed between 3 subtypes, but a trend to worse survival in mesenchymal was observed in K-NN (9.6 vs 15 ). Mesenchymal subtype presented less expression of Olig2 (p < 0.001) and SOX2 (p = 0.003) by IHC, but more YLK-40 expression (p = 0.023, SVM). On the other hand, classical subtype expressed more Nestin (p = 0.004) compared to the other subtypes (K-NN). Conclusions: In our study we have not found correlation between glioblastoma expression subtype and outcome. This large serie provides reproducible data regarding clinical-molecular-immunohistochemistry features of glioblastoma genetic subtypes.
Collapse
Affiliation(s)
- Estela Pineda
- Medical Oncology, Hospital Clinic Barcelona, Barcelona, Spain
| | | | | | | | | | - Oriol Arpi
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Medical Oncology Department, Hospital del Mar, Barcelona, Spain
| | | | - Silvia Menendez
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Medical Oncology Department, Hospital del Mar, Barcelona, Spain
| | - Teresa Ribalta
- Pathology, Hospital Clinic de Barcelona, Barcelona, Spain
| | - Noemi Vidal Sarro
- Pathology Department, Bellvitge University Hospital, Hospitalet De Llobregat, Spain
| | | | - Anna Estival
- Medical Oncology Department. Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Barcelona, Spain
| | | | - Miguel J. Gil Gil
- Breast Cancer Unit & Medical Oncology Department, Institut Català d'Oncologia, IDIBELL, Barcelona, Spain
| | | | | | - Salvador Villa
- Catalan Institute of Oncology, Germans Trias, Barcelona, Spain
| | | | - Núria de la Iglesia
- Translational Genomics and Targeted Therapeutics in Solid Tumors Lab (IDIBAPS), Medical Oncology, Hospital Clínic Barcelona, Barcelona, Spain
| | - Carmen Balana
- Institut Catala Oncologia Badalona, Hospital Germans Trias I Pujol, Badalona/Barcelona, Spain
| |
Collapse
|
14
|
Lassen‐Ramshad Y, Ozyar E, Alanyali S, Poortmans P, Van Houtte P, Sohawon S, Esassolak M, Krengli M, Villa S, Miller RC, Demiroz C, Akyurek S, Aggerholm‐Pedersen N, Thariat J. Reply to “Proper tumor classification and growth rate are key elements when considering indications and results of radiotherapy for head and neck paragangliomas”. Head Neck 2019; 41:2837-2838. [DOI: 10.1002/hed.25800] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2019] [Accepted: 04/23/2019] [Indexed: 11/07/2022] Open
Affiliation(s)
- Yasmin Lassen‐Ramshad
- Danish Centre for Particle TherapyAarhus University Hospital Aarhus Denmark
- Department of OncologyAarhus University Hospital Aarhus Denmark
| | - Enis Ozyar
- Acibadem M.A. Aydinlar UniversitySchool of Medicine, Department of Radiation Oncology Turkey
| | - Senem Alanyali
- Department of Radiation OncologyFaculty of Medicine, Ege University Turkey
| | | | - Paul Van Houtte
- Department of Radiation OncologyJules Bordet Institute Brussels Belgium
| | - Schoeb Sohawon
- Department of Radiation OncologyJules Bordet Institute Brussels Belgium
| | - Mustafa Esassolak
- Department of Radiation OncologyFaculty of Medicine, Ege University Turkey
| | - Marco Krengli
- Department of RadiotherapyUniversity of Piemonte Orientale Novara Italy
| | - Salvador Villa
- Department of Radiation OncologyCatalan Institute of Oncology Badalona Spain
| | - Robert C. Miller
- Department of Radiation OncologyMayo Clinic Jacksonville Florida
| | - Candan Demiroz
- Uludag University Faculty of MedicineRadiation Oncology Clinical Division Turkey
| | - Serap Akyurek
- Department of RadiotherapyAnkara University School of Medicine Ankara Turkey
| | | | - Juliette Thariat
- Radiation Oncology DepartmentCentre Francois Baclesse Caen France
| |
Collapse
|
15
|
Rizzi C, Finizio A, Maggi V, Villa S. Spatial-temporal analysis and risk characterisation of pesticides in Alpine glacial streams. Environ Pollut 2019; 248:659-666. [PMID: 30849583 DOI: 10.1016/j.envpol.2019.02.067] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/04/2018] [Revised: 02/20/2019] [Accepted: 02/21/2019] [Indexed: 06/09/2023]
Abstract
We analysed the spatial and temporal distribution of a selection of pesticides in Alpine glaciers used on the Po Plain in Northern Italy, near the Alps. By analysing a 102-m ice core taken from the Lys Glacier (Monte Rosa massif, Italy), we highlight historical contamination from the insecticide chlorpyrifos and the herbicide terbuthylazine, confirming the role of alpine glaciers as temporal sinks. In addition, we collected meltwater samples from six glaciers distributed along the Alpine Arc during the summer of 2016, which showed widespread contamination by pesticides. Overall, chlorpyrifos and terbuthylazine dominated the contaminant fingerprint of all of the studied glaciers, with contamination peaks occurring at the beginning of the melting season. This highlights the importance of the medium-range atmospheric transport of these pesticides in connection with agricultural practices in the areas beneath the Italian Alps, where they are widely applied. The release of pesticides in meltwater can lead to potential risks to the aquatic ecosystems of headwater streams, as we demonstrate for chlorpyrifos. This suggests that the medium-range atmospheric transport of pesticides should be considered as part of regulations to protect the water quality of these pristine environments.
Collapse
Affiliation(s)
- C Rizzi
- Dept. of Earth and Environmental Sciences, University of Milano - Bicocca, Piazza della Scienza 1, 20126, Milano, Italy
| | - A Finizio
- Dept. of Earth and Environmental Sciences, University of Milano - Bicocca, Piazza della Scienza 1, 20126, Milano, Italy
| | - V Maggi
- Dept. of Earth and Environmental Sciences, University of Milano - Bicocca, Piazza della Scienza 1, 20126, Milano, Italy
| | - S Villa
- Dept. of Earth and Environmental Sciences, University of Milano - Bicocca, Piazza della Scienza 1, 20126, Milano, Italy.
| |
Collapse
|
16
|
Rancati T, Bedini N, De Cecco L, Avuzzi B, Morlino S, Noris Chiorda B, Dispinzieri M, Villa S, Di Florio T, Badenchini F, Palorini F, Giandini T, Cicchetti A, Mancinelli E, Serafini M, De Vecchi A, Orlandi E, Valdagni R. OC-0616 Introducing information on gut microbiota into toxicity modeling: preliminary results from a trial. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31036-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
17
|
Villa S, Raoul G, Machuron F, Ferri J, Nicot R. Improvement in quality of life after botulinum toxin injection for temporomandibular disorder. Journal of Stomatology, Oral and Maxillofacial Surgery 2019; 120:2-6. [DOI: 10.1016/j.jormas.2018.10.007] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/08/2018] [Revised: 08/27/2018] [Accepted: 10/21/2018] [Indexed: 12/17/2022]
|
18
|
Lassen‐Ramshad Y, Ozyar E, Alanyali S, Poortmans P, Houtte P, Sohawon S, Esassolak M, Krengli M, Villa S, Miller R, Demiroz C, Akyurek S, Aggerholm‐Pedersen N, Thariat J. Paraganglioma of the head and neck region, treated with radiation therapy, a Rare Cancer Network study. Head Neck 2019; 41:1770-1776. [DOI: 10.1002/hed.25611] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2018] [Revised: 10/29/2018] [Accepted: 12/10/2018] [Indexed: 01/13/2023] Open
Affiliation(s)
- Yasmin Lassen‐Ramshad
- Danish Centre for Particle TherapyAarhus University Hospital Aarhus Denmark
- Department of OncologyAarhus University Hospital Aarhus Denmark
| | - Enis Ozyar
- Acibadem M.A. Aydinlar University, School of MedicineDepartment of Radiation Oncology Turkey
| | - Senem Alanyali
- Department of Radiation OncologyEge University Faculty of Medicine Turkey
| | | | - Paul Houtte
- Department of Radiation OncologyJules Bordet Institute Brussels Belgium
| | - Schoeb Sohawon
- Department of Radiation OncologyJules Bordet Institute Brussels Belgium
| | - Mustafa Esassolak
- Department of Radiation OncologyEge University Faculty of Medicine Turkey
| | - Marco Krengli
- Department of RadiotherapyUniversity of Piemonte Orientale Novara Italy
| | - Salvador Villa
- Department of Radiation OncologyCatalan Institute of Oncoloy Badalona Spain
| | - Robert Miller
- Department of Radiation Oncology, Mayo Clinic Jacksonville FL USA
| | - Candan Demiroz
- Uludag University Faculty of MedicineRadiation Oncology Clinical Division Turkey
| | - Serap Akyurek
- Department of RadiotherapyAnkara University School of Medicine Turkey
| | | | - Juliette Thariat
- Radiation Oncology DepartmentCentre Francois Baclesse Caen France
| |
Collapse
|
19
|
Torrente S, Andreani S, Badenchini F, Rancati T, Marenghi C, Avuzzi B, Morlino S, Bedini N, Villa S, Noris Chiorda B, Palorini F, Andreoli L, Di Florio T, Catanzaro M, Stagni S, Biasoni D, Torelli T, Tesone A, Nicolai N, Valdagni R. Clinical Results for an Active Surveillance Cohort with Localized Prostate Cancer Receiving RT after Exiting Active Surveillance. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.282] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
20
|
Krebs M, Carter L, Villa S, King A, Massey C, Lorens J, Darlington E, Fennell D. P2.06-09 MiST3: A Phase II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with Pembrolizumab in pts with Malignant Mesothelioma. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1264] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
|
21
|
Panciroli C, Lucente G, Cecilia O, Quiroga V, Carcereny E, Pardo J, Romeo M, Velarde J, Villa S, Balaña C. P05.81 Neurocognitive assessment in cancer patients without central nervous system disease treated with bevacizumab at week 34: an observational transversal multi-centric pilot study. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy139.407] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- C Panciroli
- Clinical Investigation Unit - Institut Catala d’Oncologia, Badalona, Spain
| | - G Lucente
- Neurology Service/Neuroscience Department - Hospital Universitari Germans Trias i Pujol, Badalona, Spain
| | - O Cecilia
- Medical Oncology Service - Hospital Clinic, Barcelona, Spain
| | - V Quiroga
- Medical Oncology Service - Institut Catala d’Oncologia, Badalona, Spain
| | - E Carcereny
- Medical Oncology Service - Institut Catala d’Oncologia, Badalona, Spain
| | - J Pardo
- Medical Oncology Service - Institut Catala d’Oncologia, Badalona, Spain
| | - M Romeo
- Medical Oncology Service - Institut Catala d’Oncologia, Badalona, Spain
| | - J Velarde
- Institut Catala d’Oncologia, Badalona, Spain
| | - S Villa
- Radiation Oncology Service - Institut Catala d’Oncologia, Badalona, Spain
| | - C Balaña
- Medical Oncology Service - Institut Catala d’Oncologia, Badalona, Spain
| |
Collapse
|
22
|
Villa S, Pillai M, Graham D, Kilgour E, Overton N, Vasudev N, Hughes A, Walker A, Dransfield S, Thistlethwaite F. TRIBE; Tyrosine kinase inhibitor therapy in renal-cell carcinoma: Immune biomarker evaluation. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy315.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
23
|
D’Angelo V, Villa S, Mysliwiec M, Donati MB, de Gaetano G. Defective Fibrinolytic and Prostacyclin-Like Activity in Human Atheromatous Plaques. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1646719] [Citation(s) in RCA: 82] [Impact Index Per Article: 13.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- V D’Angelo
- Department of Neurosurgery, Ca.-Granda Hospital, Milan, Italy
| | - S Villa
- Department of Neurosurgery, Ca.-Granda Hospital, Milan, Italy
| | - M Mysliwiec
- On leave of absence from the Haematology Clinic, Institute of Internal Diseases, Medical School, Bialystok, Poland
| | - M B Donati
- Department of Neurosurgery, Ca.-Granda Hospital, Milan, Italy
| | - G de Gaetano
- Istituto di Ricerche Farmacologiche ‘Mario Negri’, Via Eritrea, 62, 20157-Milan, Italy
| |
Collapse
|
24
|
Weber DC, Ares C, Villa S, Peerdeman SM, Renard L, Baumert BG, Lucas A, Veninga T, Pica A, Jefferies S, Ricardi U, Miralbell R, Stelmes JJ, Liu Y, Collette L, Collette S. Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: A phase-II parallel non-randomized and observation study (EORTC 22042-26042). Radiother Oncol 2018; 128:260-265. [PMID: 29960684 DOI: 10.1016/j.radonc.2018.06.018] [Citation(s) in RCA: 68] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2018] [Revised: 06/11/2018] [Accepted: 06/14/2018] [Indexed: 10/28/2022]
Abstract
PURPOSE The therapeutic strategy for non-benign meningiomas is controversial. The objective of this study was to prospectively investigate the impact of high dose radiation therapy (RT) on the progression-free survival (PFS) rate at 3 years in WHO grade II and III meningioma patients. MATERIALS AND METHODS In this multi-cohorts non-randomized phase II and observational study, non-benign meningioma patients were treated according to their WHO grade and Simpson's grade. Patients with atypical meningioma (WHO grade II) and Simpson's grade 1-3 [Arm 1] entered the non-randomized phase II study designed to show a 3-year PFS > 70% (primary endpoint). All other patients entered the 3 observational cohorts: WHO grade II Simpson grade 4-5 [Arm 2] and Grade III Simpson grade 1-3 or 4-5 [Arm 3&4] in which few patients were expected. RESULTS Between 02/2008 and 06/2013, 78 patients were enrolled into the study. This report focuses on the 56 (median age, 54 years) eligible patients with WHO grade II Simpson's grade 1-3 meningioma who received RT (60 Gy). At a median follow up of 5.1 years, the estimated 3-year PFS is 88.7%, hence significantly greater than 70%. Eight (14.3%) treatment failures were observed. The 3-year overall survival was 98.2%. The rate of late signs and symptoms grade 3 or more was 14.3%. CONCLUSIONS These data show that 3-year PFS for WHO grade II meningioma patients undergoing a complete resection (Simpson I-III) is superior to 70% when treated with high-dose (60 Gy) RT.
Collapse
Affiliation(s)
- Damien C Weber
- Center for Proton Therapy, Paul Scherrer Institute, ETH Domain, Villigen, Switzerland; Radiation Oncology Department, University Hospital of Bern, Bern, Switzerland; Radiation Oncology Department, University Hospital of Zürich, Switzerland.
| | - Carmen Ares
- Radiation Oncology Department, Geneva University Hospital, Switzerland; Department of Radiation-Oncology, MAASTRO Clinic, & GROW School for Oncology, Maastricht University Medical Centre, The Netherlands
| | - Salvador Villa
- Department of Radiation Oncology, Catalan Institut of Oncology, Hospital Germans Trias, Universitat Autònoma de Barcelona, Spain
| | - Saskia M Peerdeman
- Department of Neurosurgery, VU University Medical Center, Amsterdam, the Netherlands
| | - Laurette Renard
- Department of Radiation Oncology, University Hospital St Luc, Brussels, Belgium
| | - Brigitta G Baumert
- Department of Radiation-Oncology, MAASTRO Clinic, & GROW School for Oncology, Maastricht University Medical Centre, The Netherlands; Department of Radiation Oncology, Paracelsus Clinic Osnabrück and Univeristy of Münster, Germany
| | - Anna Lucas
- Department of Radiation Oncology, Institut Català d'Oncologia - L'Hospitalet, Barcelona, Spain
| | | | - Alessia Pica
- Center for Proton Therapy, Paul Scherrer Institute, ETH Domain, Villigen, Switzerland; Radiation Oncology Department, University Hospital of Bern, Bern, Switzerland
| | - Sarah Jefferies
- Oncology Department, Addenbrookes Hospital, Cambridge, United Kingdom
| | | | - Raymond Miralbell
- Radiation Oncology Department, Geneva University Hospital, Switzerland
| | | | - Yan Liu
- EORTC Headquarters, Brussels, Belgium
| | | | | |
Collapse
|
25
|
Felip-Falg s E, Teruel I, Domenech S, Erasun C, Garcia-Garzon JR, García Mosquera JJ, Nuñez F, Villa S, Massuet A, Velarde JM, Estival A, Balana C. C-Methionine PET (Met-PET) for a diagnosis algorithm for pseudoprogression (PsP), radiations necrosis (RN) and progression (P) after an indeterminate magnetic resonance imaging (MRI) in glioblastoma (GBM). J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.e14039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Eudald Felip-Falg s
- Medical Oncology Department, Germans Trias i Pujol Hospital, Catalan Institute of Oncology (ICO), Badalona, Spain
| | - Iris Teruel
- Medical Oncology Department. Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain
| | - Sira Domenech
- Radiology, Institut Diagnòstic per la Imatge (IDI),, Badalona/Barcelona, Spain
| | - Carlos Erasun
- Medical Oncology Department. Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain
| | | | - Juan José García Mosquera
- Medical Oncology Department. Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain
| | - Fidel Nuñez
- Radiology, Institut Diagnòstic per la Imatge (IDI),, Badalona, Spain
| | - Salvador Villa
- Catalan Institute of Oncology, Germans Trias, Barcelona, Spain
| | - Anna Massuet
- Radiology, Institut Diagnòstic per la Imatge (IDI),, Badalona, Spain
| | | | - Anna Estival
- Medical Oncology Department. Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain
| | - Carmen Balana
- Institut Catala Oncologia, Hospital Germans Trias I Pujol, Badalona, Spain
| |
Collapse
|
26
|
Salas S, Resseguier N, Blay JY, Le Cesne A, Italiano A, Chevreau C, Rosset P, Isambert N, Soulie P, Cupissol D, Delcambre C, Bay JO, Dubray-Longeras P, Krengli M, De Bari B, Villa S, Kaanders JHAM, Torrente S, Pasquier D, Thariat JO, Myroslav L, Sole CV, Dincbas HF, Habboush JY, Zilli T, Dragan T, Khan R K, Ugurluer G, Cena T, Duffaud F, Penel N, Bertucci F, Ranchere-Vince D, Terrier P, Bonvalot S, Macagno N, Lemoine C, Lae M, Coindre JM, Bouvier C. Prediction of local and metastatic recurrence in solitary fibrous tumor: construction of a risk calculator in a multicenter cohort from the French Sarcoma Group (FSG) database. Ann Oncol 2018; 28:1979-1987. [PMID: 28838212 DOI: 10.1093/annonc/mdx250] [Citation(s) in RCA: 83] [Impact Index Per Article: 13.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Background Solitary fibrous tumors (SFT) are rare unusual ubiquitous soft tissue tumors that are presumed to be of fibroblastic differentiation. At present, the challenge is to establish accurate prognostic factors. Patients and methods A total of 214 consecutive patients with SFT diagnosed in 24 participating cancer centers were entered into the European database (www.conticabase.org) to perform univariate and multivariate analysis for overall survival (OS), local recurrence incidence (LRI) and metastatic recurrence incidence (MRI) by taking competing risks into account. A prognostic model was constructed for LRI and MRI. Internal and external validations of the prognostic models were carried out. An individual risk calculator was carried out to quantify the risk of both local and metastatic recurrence. Results We restricted our analysis to 162 patients with local disease. Twenty patients (12.3%) were deceased at the time of analysis and the median OS was not reached. The LRI rates at 10 and 20 years were 19.2% and 38.6%, respectively. The MRI rates at 10 and 20 years were 31.4% and 49.8%, respectively. Multivariate analysis retained age and mitotic count tended to significance for predicting OS. The factors influencing LRI were viscera localization, radiotherapy and age. Mitotic count, tumor localization other than limb and age had independent values for MRI. Three prognostic groups for OS were defined based on the number of unfavorable prognostic factors and calculations were carried out to predict the risk of local and metastatic recurrence for individual patients. Conclusion LRI and MRI rates increased between 10 and 20 years so relapses were delayed, suggesting that long-term monitoring is useful. This study also shows that different prognostic SFT sub-groups could benefit from different therapeutic strategies and that use of a survival calculator could become standard practice in SFTs to individualize treatment based on the clinical situation.
Collapse
Affiliation(s)
- S Salas
- Department of Medicine, Timone Hospital, Marseille.,Aix Marseille University, Marseille
| | - N Resseguier
- Support Unit for Clinical Research and Economic Evaluatin, Timone Hospital, Marseille
| | - J Y Blay
- Department of Medicine, Leon Berard Center, Lyon
| | - A Le Cesne
- Department of Medicine, Gustave Roussy Institute, Villejuif
| | - A Italiano
- Department of Medicine, Bergonié Institute, Bordeaux
| | - C Chevreau
- Department of Medicine, Claudius Regaud Institute, Toulouse
| | - P Rosset
- Department of Medicine, CHU, Tours
| | - N Isambert
- Department of Medicine, Georges-François Leclerc Institute, Dijon
| | - P Soulie
- Department of Medicine, Paul Papin Institute, Angers
| | - D Cupissol
- Department of Medicine, Val d'Aurelle Institute, Montpellier
| | - C Delcambre
- Department of Medicine, François-Baclesse Institute, Caen
| | - J O Bay
- Department of Medicine, Jean Perrin Institute, Clermont-Ferrand, France
| | - P Dubray-Longeras
- Department of Medicine, Jean Perrin Institute, Clermont-Ferrand, France
| | - M Krengli
- Department of Radiotherapy, University Hospital, Novara, Italy
| | - B De Bari
- Department of Radiotherapy, CHU Vaudois, Lausanne, Switzerland
| | - S Villa
- Department of Radiotherapy, Catalan Institute of Oncology, Badalona Catalonia, Spain
| | - J H A M Kaanders
- Department of Radiotherapy, Radboud University Medical Center, Nijmegen, The Netherlands
| | - S Torrente
- Department of Radiotherapy, University Hospital, Novara, Italy
| | - D Pasquier
- Department of Radiotherapy, Centre Oscar Lambret, Lille
| | - J O Thariat
- Department of Radiotherapy, Centre Antoine-Lacassagne, Nice, France
| | - L Myroslav
- Department of Radiotherapy, Rambam HCC, Haifa, Israel
| | - C V Sole
- Department of Radiotherapy, Clinica Instituto de Radiomedicina (IRAM), Santiago, Chile
| | - H F Dincbas
- Department of Radiotherapy, Cerrahpasa Medical Faculty, Istanbul, Turkey
| | - J Y Habboush
- Department of Radiotherapy, Mayo Clinic, Jacksonville, USA
| | - T Zilli
- Department of Radiotherapy, HUG, Geneva, Switzerland
| | - T Dragan
- Department of Radiotherapy, Institut J. Bordet Brussels, Brussels, Belgium
| | - K Khan R
- Department of Radiotherapy, CHVR, Sion, Switzerland
| | - G Ugurluer
- Department of Radiotherapy, Adana Hospital, Adana, Turkey
| | - T Cena
- Department of Medical Statistics, University of Piemonte Orientale, Novara, Italy
| | - F Duffaud
- Department of Medicine, Timone Hospital, Marseille
| | - N Penel
- Department of Medicine, Oscar Lambret Institute, Lille
| | - F Bertucci
- Department of Medicine, Paoli Calmette Institute, Marseille
| | | | - P Terrier
- Department of Pathology, Gustave Roussy Institute, Villejuif
| | - S Bonvalot
- Department of Surgery, Institut Curie, PSL University, Paris
| | - N Macagno
- Department of Pathology, Timone Hospital, Marseille
| | - C Lemoine
- Support Unit for Clinical Research and Economic Evaluatin, Timone Hospital, Marseille
| | - M Lae
- Department of Pathology, Curie Institute, Paris
| | - J M Coindre
- Department of Pathology, Bergonié Institute, Bordeaux.,University Victor Ségalen, Bordeaux, France
| | - C Bouvier
- Aix Marseille University, Marseille.,Department of Pathology, Timone Hospital, Marseille
| |
Collapse
|
27
|
Barni S, Ardizzoia A, Bernardo G, Villa S, Strada MR, Cazzaniga M, Archili C, Frontini L. Vinorelbine as Single Agent in Pretreated Patients with Advanced Breast Cancer. Tumori 2018; 80:280-2. [PMID: 7974798 DOI: 10.1177/030089169408000407] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Vinorelbine is a new semisynthetic vinca alkaloid with high activity against breast cancer. In this multicenter clinical study we evaluated the activity and toxicity of vinorelbine as a single agent in 30 advanced breast cancer patients pretreated with anthracycline and/or mitoxantrone (24 with recurrent tumor, 6 with non operable cancers). Vinorelbine was given at a weekly dose of 20 mg/m2 for a minimum of 3 weeks. Treatment was continued until there was disease progression or evidence of serious toxicity. Predominant sites of metastasis were viscera (14 cases), soft tissue (11 cases) and bone (5 cases). A median number of 12 doses of vinorelbine (range 3-34) were administered to each patient. Objective responses were recorded in 11 of them and 15 had minimal responses or stable disease. Four patients showed progression of disease during vinorelbine chemotherapy. The median duration of response was 5 months (2-14). The median survival time was 7 months (2-20+): 9 months for responders and 5 months for those with stable or progressive disease. The most important and dose-limiting toxicity was represented by leukopenia. The compliance of patients was very good and the treatment was well accepted by them all including those with low performance status. In conclusion, this study provides further evidence that a weekly schedule with vinorelbine as a single agent is effective and well-tolerated also in pretreated advanced breast cancer patients.
Collapse
Affiliation(s)
- S Barni
- Divisione di Radioterapia Oncologica, Ospedale S. Gerardo, Monza, Italy
| | | | | | | | | | | | | | | |
Collapse
|
28
|
Paolorossi F, Villa S, Barni S, Tancini G, Andres M, Lissoni P. Second-Line Therapy with Interferon-Alpha plus Vinblastine in Metastatic Renal Cell Cancer Patients Progressed under Interleukin-2 Subcutaneous Immunotherapy. Tumori 2018; 81:45-7. [PMID: 7754541 DOI: 10.1177/030089169508100111] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Aims and background Interferon (IFN) ± vinblastine (VNB) has appeared to be effective as first–line therapy of metastatic renal cell cancer. This study was performed to establish the efficacy of IFN plus VNB in metastatic RCC previously treated with interleukin-2 (IL-2). Methods The study included 14 metastatic renal cell cancer patients who did not respond to IL-2 subcutaneous therapy or who relapsed after initial response or stable disease. IFN-alpha 2a was given subcutaneously at 3 million U thrice a week in association with VNB (0.1 mg/kg i.v. every 21 days) until progression or toxicity. Patients were considered as evaluable when they were treated for at least 1 month. Results Evaluable patients were 13/14. No patient had a complete response. Partial response was achieved in 2/13 (15%) patients. Stable disease was seen in 5/13 patients, and the last 6 progressed. Conclusions This study, by showing a tumor response rate comparable to that reported with first-line therapy, suggests that previous IL-2 immunotherapy does not influence negatively the efficacy of IFN + VNB in metastatic renal cell cancer.
Collapse
Affiliation(s)
- F Paolorossi
- Divisione di Radioterapia Oncologica, Ospedale San Gerardo, Milano, Italy
| | | | | | | | | | | |
Collapse
|
29
|
Abstract
The authors report a case of ischemic cardiopathy that occured during therapy with CDDP in a woman with an ovarian cancer which had been extensively pre-treated with adriamycin.
Collapse
|
30
|
Abstract
Mitomycin C was administered to 22 patients with metastatic breast cancer, refractory to hormonal therapy and conventional chemotherapy. Treatment was given by intravenous bolus injection at 20 mg/m2 of the drug and repeated at 6-week intervals. The overall response rate was 23 %. Two complete remissions were seen in soft tissue lesions. Leukopenia occurred in 68 % of the patients, thrombocytopenia in 36 %, and anemia in 14 %. One case of cardiotoxicity after previous treatment with adriamycin was observed. We conclude that mitomycin C is an active agent in disseminated breast cancer resistant to hormone therapy and chemotherapy. Combination of mitomycin C with other chemotherapeutic drugs will be tested.
Collapse
|
31
|
Tomirotti M, Perrone S, Giè P, Canaletti R, Carpi A, Biasoli R, Lombardi F, Giovanninetti A, Mensi F, Villa S. Cisplatin (P) versus Cyclophosphamide, Adriamycin and Cisplatin (CAP) for Stage III-IV Epithelial Ovarian Carcinoma: A Prospective Randomized Trial. Tumori 2018; 74:573-7. [PMID: 3217992 DOI: 10.1177/030089168807400514] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
In 1982 a randomized trial was started to compare a cisplatin-containing polychemotherapy (CAP: cyclophosphamide - CPA 750 mg/m2, adriamycin - ADM 50 mg/m2, cisplatin - P 50 mg/m2 on day 1 every 21 days) with full-dose cisplatin as single agent (P 60 mg/m2/day on days 1 and 2 every 28 days) in 44 patients undergoing exploratory laparotomy or debulking sugery for stage III-IV epithelial ovarian carcinoma with residual disease > 5 cm. The response was evaluated at second-look surgery with random biopsies and peritoneal washing. On the basis of the final results the authors underline some data which, although merely indicative (because of the small number of patients) appear to be worth considering since they are in accordance with the latest reports: a) similar response rate (CR+PR=47%) to first-line treatment in the two groups; b) the CAP treatment may achieve a longer median duration of CRs than the P treatment (20 versus 11 months); c) overall survival seems similar in the two groups of patients (19 versus 18 months), whereas the survival of CRs seems longer in the CAP treated patients (> 32 versus 25 months). The authors also discuss some observations on a possible salvage therapy.
Collapse
Affiliation(s)
- M Tomirotti
- Servizio di Oncologia Medica e Chemioterapia, Ospedale Fatebenefratelli e Oftalmico, Milano, Italia
| | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Atalar B, Ozsahin M, Call J, Napieralska A, Kamer S, Villa S, Erpolat P, Negretti L, Lassen-Ramshad Y, Onal C, Akyurek S, Ugurluer G, Baumert BG, Servagi-Vernat S, Miller RC, Ozyar E, Sio TT. Treatment outcome and prognostic factors for adult patients with medulloblastoma: The Rare Cancer Network (RCN) experience. Radiother Oncol 2018; 127:96-102. [DOI: 10.1016/j.radonc.2017.12.028] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2017] [Revised: 11/30/2017] [Accepted: 12/19/2017] [Indexed: 12/31/2022]
|
33
|
Cattò C, James G, Villa F, Villa S, Cappitelli F. Zosteric acid and salicylic acid bound to a low density polyethylene surface successfully control bacterial biofilm formation. Biofouling 2018; 34:440-452. [PMID: 29726716 DOI: 10.1080/08927014.2018.1462342] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/10/2018] [Accepted: 03/27/2018] [Indexed: 06/08/2023]
Abstract
The active moieties of the anti-biofilm natural compounds zosteric (ZA) and salicylic (SA) acids have been covalently immobilized on a low density polyethylene (LDPE) surface. The grafting procedure provided new non-toxic eco-friendly materials (LDPE-CA and LDPE-SA) with anti-biofilm properties superior to the conventional biocide-based approaches and with features suitable for applications in challenging fields where the use of antimicrobial agents is limited. Microbiological investigation proved that LDPE-CA and LDPE-SA: (1) reduced Escherichia coli biofilm biomass by up to 61% with a mechanism that did not affect bacterial viability; (2) significantly affected biofilm morphology, decreasing biofilm thickness, roughness, substratum coverage, cell and matrix polysaccharide bio-volumes by >80% and increasing the surface to bio-volume ratio; (3) made the biofilm more susceptible to ampicillin and ethanol. Since no molecules were leached from the surface, they remained constantly effective and below the lethal level; therefore, the risk of inducing resistance was minimized.
Collapse
Affiliation(s)
- C Cattò
- a Department of Food Environmental and Nutritional Sciences , Università degli Studi di Milano , Milan , Italy
- b Center for Biofilm Engineering , Montana State University , Bozeman , MT , USA
| | - G James
- b Center for Biofilm Engineering , Montana State University , Bozeman , MT , USA
| | - F Villa
- a Department of Food Environmental and Nutritional Sciences , Università degli Studi di Milano , Milan , Italy
| | - S Villa
- c Department of Pharmaceutical Sciences , Università degli Studi di Milano , Milan , Italy
| | - F Cappitelli
- a Department of Food Environmental and Nutritional Sciences , Università degli Studi di Milano , Milan , Italy
| |
Collapse
|
34
|
Miner KR, Blais J, Bogdal C, Villa S, Schwikowski M, Pavlova P, Steinlin C, Gerbi C, Kreutz KJ. Legacy organochlorine pollutants in glacial watersheds: a review. Environ Sci Process Impacts 2017; 19:1474-1483. [PMID: 29140398 DOI: 10.1039/c7em00393e] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Northern Hemisphere alpine glaciers have been identified as a point of concentration and reemergence of legacy organochlorine pollutants (OCPs). In this review, we compile a selection of published literature combining long-range, global atmospheric transport and distribution-based compartmental environmental flux models, as well as data from glacial meltwater, ice core, crevasse and proglacial lake sediment studies. Regional studies of ice and meltwater in alpine glaciers of the northern latitudes show similarities in sample deposition profiles and concentration due to chemical atmospheric residence time, precipitation type and glacier flow rates. In glaciated locations near areas of extensive OCPs use, such as the Swiss and Italian Alps, glacier sample concentrations are higher, while in areas more distant from use, including Arctic nations, OCPs concentrations in glaciers are significantly lower. Our review identifies alpine glaciers co-located with regions characterized by OCPs use as a significant organochlorine pollutant distribution source, secondary in timing and location to direct deposition, with subsequent bioaccumulation and potential human risk impacts.
Collapse
Affiliation(s)
- K R Miner
- School of Earth and Climate Sciences, University of Maine, Orono, ME 04469, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Balana C, Teruel I, Estival A, Verger E, Sepulveda J, Pineda E, Garcia MM, Gallego O, Luque R, Gil MG, Mesia C, Barco SD, Velarde JM, Mosquera JJG, Herrero A, Villa S, de las Penas R. ACTR-48. AN APPRAISAL OF THE IMPACT ON SURVIVAL OF NEOADJUVANT TREATMENTS DELAYING RADIOTHERAPY IN ‘ONLY-BIOPSIED GLIOBLASTOMA’ TRIALS CONDUCTED BY THE GEINO GROUP COMPARED TO PATIENTS TREATED WITH THE STUPP’S REGIME. EXPERIENCE OF THE GEINO AND THE GLIOCAT GROUP. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox168.039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Villa F, Colombo I, Crippa A, De Martini G, Lafranconi M, Dell'Oro S, Vittimberga I, Arnoffi J, Guida F, Villa S, Anghilieri M, Viganò C, Ferrando P, De Nittis G, Valsecchi V, Ardizzoia A. Sharing long term follow-up of breast cancer survivors with family physician: a province of Lecco experience. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx433] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
37
|
Gil-Gil M, Velarde J, Martinez-Garcia M, Gallego O, del Barco S, Pineda E, Mesia C, Estival A, Vilariño N, Marruecos J, Verger E, Craven J, Fuentes R, Lucas A, Macià M, Carrato C, Vidal N, Velasco R, Villa S, Balana C. Treatment of recurrent glioblastoma (GB) after radiotherapy (RT) and temozolomide (TMZ): A retrospective analysis of the GLIOCAT study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx366.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
38
|
Di Nica V, Gallet J, Villa S, Mezzanotte V. Toxicity of Quaternary Ammonium Compounds (QACs) as single compounds and mixtures to aquatic non-target microorganisms: Experimental data and predictive models. Ecotoxicol Environ Saf 2017; 142:567-577. [PMID: 28494277 DOI: 10.1016/j.ecoenv.2017.04.028] [Citation(s) in RCA: 45] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/17/2017] [Revised: 03/24/2017] [Accepted: 04/13/2017] [Indexed: 05/07/2023]
Abstract
The toxic effects of five Quaternary Ammonium Compounds (QACs) that are widely used as active ingredients in personal care products were assessed using the bioluminescent bacterium Aliivibrio fischeri (formerly Vibrio fischeri) (Microtox® test system). The experimental results showed a relevant toxicity for almost all of the single QACs, with IC50 values lower than 1mgL-1. Analysis of the mode of action through the application of the Quantitative Structure-Activity Relationship (QSAR) models indicated an a-specific reactivity for most of the QACs toward A. fischeri. Only hexadecyl trimethyl ammonium chloride (ATMAC-16) behaved as a polar-narcotic, with a low reactivity toward the bacterial cell membrane. The concentration response curves of the different binary and multicomponent mixtures of QACs were also evaluated with respect to the predictions from the Concentration Addition (CA) and Independent Action (IA) models. For almost all of the binary and multicomponent mixtures (7 out of 11 mixtures tested), an agreement between the experimental and predicted ICx was observed and confirmed via application of the Model Deviation Ratio (MDR). In four cases, some deviations from the expected behaviour were observed (potential antagonistic and synergistic interactions) at concentrations on the order of hundreds of µgL-1, which could be of environmental concern, especially in the case of synergistic effects. The analysis of aquatic ecotoxicity data and the few available values of the measured environmental concentrations (MECs) from the literature for wastewaters and receiving waterbodies suggest that a potential risk toward aquatic life cannot be excluded.
Collapse
Affiliation(s)
- V Di Nica
- Dept. of Earth and Environmental Sciences, University of Milano Bicocca, Piazza della Scienza 1, 20126 Milano, Italy.
| | - J Gallet
- Unités de Formation et de Recherche - Sciences Fondamentales et Appliquées, Université Savoie Mont-Blanc, Le Bourget du Lac Cedex 73376, France
| | - S Villa
- Dept. of Earth and Environmental Sciences, University of Milano Bicocca, Piazza della Scienza 1, 20126 Milano, Italy
| | - V Mezzanotte
- Dept. of Earth and Environmental Sciences, University of Milano Bicocca, Piazza della Scienza 1, 20126 Milano, Italy
| |
Collapse
|
39
|
Carrara M, Giandini T, Bonfantini F, Avuzzi B, Villa S, Bedini N, Morlino S, Carabelli G, Frasca S, Valdagni R, Pignoli E. Analysis of electromagnetic transponders tracking data to quantify intrafraction prostate motion during radiotherapy treatments. ACTA ACUST UNITED AC 2017. [DOI: 10.1088/1742-6596/777/1/012036] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
40
|
Legnani L, Colombo D, Venuti A, Pastori C, Lopalco L, Toma L, Mori M, Grazioso G, Villa S. Diazabicyclo analogues of maraviroc: synthesis, modeling, NMR studies and antiviral activity. Medchemcomm 2017; 8:422-433. [PMID: 30108760 PMCID: PMC6071814 DOI: 10.1039/c6md00575f] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/14/2016] [Accepted: 12/12/2016] [Indexed: 01/07/2023]
Abstract
Two diazabicyclo analogues of maraviroc, in which the azabicyclooctane moiety is replaced by diazabicyclooctane or diazabicyclononane, were synthesized and tested, through a viral neutralization assay, on a panel of six pseudoviruses. The diazabicyclooctane derivative maintained a significant infectivity reduction power, whereas the diazabicyclononane was less effective. Biological data were rationalized through a computational study that allowed the conformational preferences of the compounds to be determined and a correlation between the inhibitory activity, the bridge length of the bicycle, and the rotational barrier around dihedral angle τ7 to be hypothesized. A high-field NMR analysis supported the modeling results.
Collapse
Affiliation(s)
- L Legnani
- Dipartimento di Chimica , Università di Pavia , Via Taramelli 12 , 27100 Pavia , Italy
- Dipartimento di Scienze del Farmaco , Università di Catania , V.le A. Doria 6 , 95125 Catania , Italy
| | - D Colombo
- Dipartimento di Biotecnologie Mediche e Medicina Traslazionale , Università di Milano , Via Saldini 50 , 20133 Milano , Italy
| | - A Venuti
- Division of Immunology, Transplantation and Infectious Diseases , San Raffaele Scientific Institute , Milan , Italy
| | - C Pastori
- Division of Immunology, Transplantation and Infectious Diseases , San Raffaele Scientific Institute , Milan , Italy
| | - L Lopalco
- Division of Immunology, Transplantation and Infectious Diseases , San Raffaele Scientific Institute , Milan , Italy
| | - L Toma
- Dipartimento di Chimica , Università di Pavia , Via Taramelli 12 , 27100 Pavia , Italy
| | - M Mori
- Dipartimento di Scienze Farmaceutiche , Università di Milano , Via L. Mangiagalli 25 , 20133 Milano , Italy . ; ; Tel: +39 02 503 19368
| | - G Grazioso
- Dipartimento di Scienze Farmaceutiche , Università di Milano , Via L. Mangiagalli 25 , 20133 Milano , Italy . ; ; Tel: +39 02 503 19368
| | - S Villa
- Dipartimento di Scienze Farmaceutiche , Università di Milano , Via L. Mangiagalli 25 , 20133 Milano , Italy . ; ; Tel: +39 02 503 19368
| |
Collapse
|
41
|
Boladeras A, Ferrer F, Navarro V, De Blas R, Cunillera O, Mateo D, Gutierrez C, Villa S, Martinez E, Pera J, Ferrer M, Guedea F. Association Between Dose-Volume Histograms and Health-Related Quality of Life in Patients with Prostate Cancer Treated with External Beam Radiation Therapy. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.1340] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
42
|
Krengli M, De Bari B, Villa S, Kaanders J, Torrente S, Pasquier D, Thariat J, Myroslav L, Sole C, Dincbas H, Habboush J, Zilli T, Dragan T, Khanfir K, Ugurluer G, Cena T. Radiation Therapy for Extracranial Hemangiopericytoma/Solitary Fibrous Tumor: A Study From the Rare Cancer Network. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.2399] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
43
|
Comas S, Villa S, Velarde J, Molero J, Estival A, Teixidor P, Guitierrez B, Luis Y, Perez G, Panciroli C, Balana C. Lack of Evidence That High Dose of Radiation in Subventricle Zone (SVZ) Can Improve the Outcome in Glioblastoma (GB): Report on a Cohort of Patients. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.820] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
44
|
Bolla M, Maingon P, Carrie C, Villa S, Kitsios P, Poortmans PM, Sundar S, van der Steen-Banasik EM, Armstrong J, Bosset JF, Herrera FG, Pieters B, Slot A, Bahl A, Ben-Yosef R, Boehmer D, Scrase C, Renard L, Shash E, Coens C, van den Bergh AC, Collette L. Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991. J Clin Oncol 2016; 34:1748-56. [DOI: 10.1200/jco.2015.64.8055] [Citation(s) in RCA: 147] [Impact Index Per Article: 18.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
Purpose Up to 30% of patients who undergo radiation for intermediate- or high-risk localized prostate cancer relapse biochemically within 5 years. We assessed if biochemical disease-free survival (DFS) is improved by adding 6 months of androgen suppression (AS; two injections of every-3-months depot of luteinizing hormone–releasing hormone agonist) to primary radiotherapy (RT) for intermediate- or high-risk localized prostate cancer. Patients and Methods A total of 819 patients staged: (1) cT1b-c, with prostate-specific antigen (PSA) ≥ 10 ng/mL or Gleason ≥ 7, or (2) cT2a (International Union Against Cancer TNM 1997), with no involvement of pelvic lymph nodes and no clinical evidence of metastatic spread, with PSA ≤ 50 ng/mL, were centrally randomized 1:1 to either RT or RT plus AS started on day 1 of RT. Centers opted for one dose (70, 74, or 78 Gy). Biochemical DFS, the primary end point, was defined from entry until PSA relapse (Phoenix criteria) and clinical relapse by imaging or death of any cause. The trial had 80% power to detect hazard ratio (HR), 0.714 by intent-to-treat analysis stratified by dose of RT at the two-sided α = 5%. Results The median patient age was 70 years. Among patients, 74.8% were intermediate risk and 24.8% were high risk. In the RT arm, 407 of 409 patients received RT; in the RT plus AS arm, 403 patients received RT plus AS and three patients received RT only. At 7.2 years median follow-up, RT plus AS significantly improved biochemical DFS (HR, 0.52; 95% CI, 0.41 to 0.66; P < .001, with 319 events), as well as clinical progression-free survival (205 events, HR, 0.63; 95% CI, 0.48 to 0.84; P = .001). In exploratory analysis, no statistically significant interaction between treatment effect and dose of RT could be evidenced (heterogeneity P = .79 and P = .66, for biochemical DFS and progression-free survival, respectively). Overall survival data are not mature yet. Conclusion Six months of concomitant and adjuvant AS improves biochemical and clinical DFS of intermediate- and high-risk cT1b-c to cT2a (with no involvement of pelvic lymph nodes and no clinical evidence of metastatic spread) prostatic carcinoma, treated by radiation.
Collapse
Affiliation(s)
- Michel Bolla
- Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon–Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der
| | - Philippe Maingon
- Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon–Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der
| | - Christian Carrie
- Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon–Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der
| | - Salvador Villa
- Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon–Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der
| | - Petros Kitsios
- Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon–Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der
| | - Philip M.P. Poortmans
- Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon–Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der
| | - Santhanam Sundar
- Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon–Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der
| | - Elzbieta M. van der Steen-Banasik
- Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon–Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der
| | - John Armstrong
- Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon–Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der
| | - Jean-François Bosset
- Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon–Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der
| | - Fernanda G. Herrera
- Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon–Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der
| | - Bradley Pieters
- Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon–Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der
| | - Annerie Slot
- Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon–Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der
| | - Amit Bahl
- Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon–Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der
| | - Rahamim Ben-Yosef
- Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon–Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der
| | - Dirk Boehmer
- Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon–Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der
| | - Christopher Scrase
- Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon–Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der
| | - Laurette Renard
- Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon–Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der
| | - Emad Shash
- Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon–Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der
| | - Corneel Coens
- Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon–Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der
| | - Alphonsus C.M. van den Bergh
- Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon–Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der
| | - Laurence Collette
- Michel Bolla, Centre Hospitalier Universitaire de Grenoble, Grenoble; Philippe Maingon, Georges-Francois-Leclerc Centre, Dijon; Christian Carrie, Leon Bérard Center, Lyon; Jean-François Bosset, University Hospital of Besancon–Jean Minjoz Hospital, Besancon, France; Salvador Villa, University Hospital Germans Trias I Pujol, Barcelona, Spain; Petros Kitsios, Bank of Cyprus Oncology Centre, Nicosia, Cyprus; Philip M.P. Poortmans, Radboud University Medical Center Nijmegen, Nijmegen; Elzbieta M. van der
| |
Collapse
|
45
|
Wick W, Gorlia T, Bady P, Platten M, van den Bent MJ, Taphoorn MJ, Steuve J, Brandes AA, Hamou MF, Wick A, Kosch M, Weller M, Stupp R, Roth P, Golfinopoulos V, Frenel JS, Campone M, Ricard D, Marosi C, Villa S, Weyerbrock A, Hopkins K, Homicsko K, Lhermitte B, Pesce G, Hegi ME. Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082). Clin Cancer Res 2016; 22:4797-4806. [DOI: 10.1158/1078-0432.ccr-15-3153] [Citation(s) in RCA: 90] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2015] [Accepted: 04/03/2016] [Indexed: 11/16/2022]
|
46
|
Palorini F, Rancati T, Cicchetti A, Improta I, Cozzarini C, Casanova Borca V, Degli Esposti C, Franco P, Garibaldi E, Girelli G, Maggio A, Micera R, Palombarini M, Pierelli A, Pignoli E, Simoni N, Vavassori V, Villa S, Valdagni R, Fiorino C. PO-0875: Multivariable models for urinary symptoms at 6-24 months after radical RT of prostate cancer. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)32125-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
47
|
Giandini T, Carrara M, Pignoli E, Bedini N, Morlino S, Bosetti D, Avuzzi B, Villa S, Hasegawa A, Russo S, Vischioni B, Ciocca M, Valvo F, Jereczek-Fossa B, Ciardo D, Zerini D, Colangione S, Fodor C, Cattani F, Valdagni R, Orecchia R. EP-1374: Contouring guideline optimisation for prostate pts undergoing carbon ions/photons combined treatment. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)32624-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
48
|
Boladeras A, Martinez E, Ferrer F, Gutierrez C, Villa S, Pera J, Guedea F. Localized prostate cancer treated with external beam radiation therapy: Long-term outcomes at a European comprehensive cancer centre. Rep Pract Oncol Radiother 2016; 21:181-7. [PMID: 27601948 DOI: 10.1016/j.rpor.2015.12.002] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2015] [Revised: 09/07/2015] [Accepted: 12/01/2015] [Indexed: 10/22/2022] Open
Abstract
AIMS AND BACKGROUND To present survival and toxicity outcomes in patients with clinically localized, non-metastatic prostate cancer (PCa) treated with external beam radiotherapy (EBRT) combined with androgen deprivation therapy (ADT). MATERIALS AND METHODS Retrospective study of 849 PCa patients (pts) treated from 1996 to 2005. Until August 2000, all patients (281) were treated with conventional dose EBRT (<76 Gy); subsequent pts received ≥76 Gy (565 pts). Median age was 70 years (range, 39-82). Most pts were intermediate (353; 42.8%) or high-risk (344; 41.7%). Mean PSA was 10.1 ng/ml. Median dose to the prostate was 75 Gy. Complete ADT was administered to 525 pts (61.8%). RESULTS Median follow-up was 109.6 months (range, 68.3-193.4). Overall survival (OS) was 92.5% and 81.1% at 5 and 10 years; by risk group (low, intermediate, high), 5- and 10-year OS rates were 94.3% and 85.9%, 92.3% and 79.2%, and 91.9% and 80.2% (p = 0.728). Five- and 10-year BRFS was 94.1% and 80.6% (low risk), 86.4% and 70.9% (intermediate), and 85.2% and 71.4% (high) (p = 0.0666). Toxicity included rectitis: grade 1 (G1) (277 pts; 32.6%), G2 (108; 12.7%), and G3 (20; 2.6%) and urethritis: G1 (294; 34.6%); G2 (223; 26.2%), and G3 (11; 1.3%). By dose rate (<76 Gy vs. ≥76 Gy), 5 and 10-year BRFS rates were 83.1% and 68.3% vs. 88.4% and 74.8% (p = 0.038). CONCLUSIONS Our results are comparable to other published series in terms of disease control and toxicity. These findings confirm the need for dose escalation to achieve better biochemical control and the benefits of ADT in high-risk PCa patients.
Collapse
Affiliation(s)
- Anna Boladeras
- Department of Radiation Oncology, Catalan Institute of Oncology, Universidad de Barcelona, l'Hospitalet de Llobregat, Barcelona, Spain
| | - Evelyn Martinez
- Department of Radiation Oncology, Catalan Institute of Oncology, Universidad de Barcelona, l'Hospitalet de Llobregat, Barcelona, Spain
| | - Ferran Ferrer
- Department of Radiation Oncology, Catalan Institute of Oncology, Universidad de Barcelona, l'Hospitalet de Llobregat, Barcelona, Spain
| | - Cristina Gutierrez
- Department of Radiation Oncology, Catalan Institute of Oncology, Universidad de Barcelona, l'Hospitalet de Llobregat, Barcelona, Spain
| | - Salvador Villa
- Department of Radiation Oncology, Hospital Germans Trias i Pujol, Catalan Institute of Oncology, Badalona, Barcelona, Spain
| | - Joan Pera
- Department of Radiation Oncology, Catalan Institute of Oncology, Universidad de Barcelona, l'Hospitalet de Llobregat, Barcelona, Spain
| | - Ferran Guedea
- Department of Radiation Oncology, Catalan Institute of Oncology, Universidad de Barcelona, l'Hospitalet de Llobregat, Barcelona, Spain
| |
Collapse
|
49
|
Palorini F, Rancati T, Cicchetti A, Improta I, Cozzarini C, Borca VC, Degli Esposti C, Franco P, Garibaldi E, Girelli G, Maggio A, Botti A, Palombarini M, Pierelli A, Pignoli E, Simoni N, Vavassori V, Villa S, Valdagni R, Fiorino C. Clinical and dose predictors for the incidence of late urinary symptoms after radical radiotherapy for prostate cancer. Phys Med 2016. [DOI: 10.1016/j.ejmp.2016.01.170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
50
|
D'Angelo G, Villa C, Tamborini A, Villa S. Evaluation of the main coagulation tests in the presence of hemolysis in healthy subjects and patients on oral anticoagulant therapy. Int J Lab Hematol 2015; 37:819-33. [DOI: 10.1111/ijlh.12417] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2015] [Accepted: 07/14/2015] [Indexed: 11/29/2022]
Affiliation(s)
- G. D'Angelo
- Laboratorio di Chimica-Clinica, Ematologia e Microbiologia; Azienda Ospedaliera ‘S. Antonio Abate’ - Gallarate; Varese Italy
| | - C. Villa
- Laboratorio di Chimica-Clinica, Ematologia e Microbiologia; Azienda Ospedaliera ‘S. Antonio Abate’ - Gallarate; Varese Italy
| | - A. Tamborini
- Laboratorio di Chimica-Clinica, Ematologia e Microbiologia; Azienda Ospedaliera ‘S. Antonio Abate’ - Gallarate; Varese Italy
| | - S. Villa
- Laboratorio di Chimica-Clinica, Ematologia e Microbiologia; Azienda Ospedaliera ‘S. Antonio Abate’ - Gallarate; Varese Italy
| |
Collapse
|